NASDAQ:SNTI Senti Biosciences (SNTI) Stock Price, News & Analysis $2.21 +0.01 (+0.45%) Closing price 04:00 PM EasternExtended Trading$2.22 +0.01 (+0.45%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Senti Biosciences Stock (NASDAQ:SNTI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Senti Biosciences alerts:Sign Up Key Stats Today's Range$2.10▼$2.3450-Day Range$1.99▼$3.8452-Week Range$1.52▼$16.94Volume94,812 shsAverage Volume653,829 shsMarket Capitalization$57.64 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingBuy Company Overview Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Read More Senti Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreSNTI MarketRank™: Senti Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 470th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSenti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSenti Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Senti Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Senti Biosciences are expected to grow in the coming year, from ($14.54) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Senti Biosciences is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Senti Biosciences is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSenti Biosciences has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Senti Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.56% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently increased by 79.24%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSenti Biosciences does not currently pay a dividend.Dividend GrowthSenti Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.56% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently increased by 79.24%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.40 News SentimentSenti Biosciences has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Senti Biosciences this week, compared to 1 article on an average week.Search Interest2 people have searched for SNTI on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Senti Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.12% of the stock of Senti Biosciences is held by insiders.Percentage Held by InstitutionsOnly 25.73% of the stock of Senti Biosciences is held by institutions.Read more about Senti Biosciences' insider trading history. Receive SNTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SNTI Stock News HeadlinesNASDAQ:SNTI Financials | Senti Biosciences Inc - Investing.comJuly 3, 2025 | investing.comSNTI - Senti Biosciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comM$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 7 at 2:00 AM | Brownstone Research (Ad)Senti Bio Participates in Nasdaq Amplify Spotlight SeriesJune 30, 2025 | globenewswire.comSenti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies - NasdaqJune 26, 2025 | nasdaq.comSenti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) ConferenceJune 24, 2025 | globenewswire.comSenti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid LeukemiaJune 18, 2025 | globenewswire.comSenti Biosciences Announces New Employment Inducement GrantsJune 9, 2025 | globenewswire.comSee More Headlines SNTI Stock Analysis - Frequently Asked Questions How have SNTI shares performed this year? Senti Biosciences' stock was trading at $3.51 at the start of the year. Since then, SNTI stock has decreased by 37.0% and is now trading at $2.21. How were Senti Biosciences' earnings last quarter? Senti Biosciences, Inc. (NASDAQ:SNTI) released its earnings results on Tuesday, May, 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.85. The firm had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.30 million. When did Senti Biosciences' stock split? Senti Biosciences shares reverse split on Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Senti Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI). Company Calendar Last Earnings5/06/2025Today7/07/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNTI CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+288.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($10.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-177.24% Return on Assets-67.38% Debt Debt-to-Equity RatioN/A Current Ratio4.22 Quick Ratio4.22 Sales & Book Value Annual Sales$2.56 million Price / Sales22.31 Cash FlowN/A Price / Cash FlowN/A Book Value$5.31 per share Price / Book0.41Miscellaneous Outstanding Shares26,080,000Free Float25,267,000Market Cap$57.12 million OptionableNot Optionable Beta2.09 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:SNTI) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.